STOCK TITAN

Poolbeg Pharma PLC Announces Result of AGM

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Poolbeg Pharma, a UK-based biopharmaceutical company, announced that all resolutions presented at their Annual General Meeting on June 17, 2024, were approved by shareholders. The company, traded under AIM:POLB and OTCQB:POLBF, focuses on developing and commercializing innovative medicines for diseases with high unmet medical needs. This successful AGM marks a positive step for Poolbeg as they continue their mission to address critical health challenges.

Positive
  • All resolutions at the AGM were approved by shareholders.
  • Poolbeg Pharma continues to focus on developing medicines for diseases with high unmet medical needs.
  • The successful AGM suggests shareholder confidence in the company's direction and strategies.
Negative
  • The press release lacks specific financial data, clinical updates, or future business strategies which are critical for detailed investor analysis.

Results of Annual General Meeting

LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ‘Poolbeg' or the ‘Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that all resolutions put to shareholders at the Company's Annual General Meeting held earlier today were duly passed.

Enquiries

Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O'Connell, CFO

+44 (0) 207 183 1499

Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

+44 (0) 207 220 0500

Shore Capital Stockbrokers Ltd (Joint Broker)

David Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel Jones (Corporate Broking)

+44 (0) 207 408 4090

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist

+353 (0) 1 679 6363

Optimum Strategic Communications

Nick Bastin, Vici Rabbetts, Elena Bates

+44 (0) 208 078 4357

poolbeg@optimumcomms.com

About Poolbeg Pharma

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.

Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Poolbeg Pharma PLC



View the original press release on accesswire.com

FAQ

What was the outcome of Poolbeg Pharma's AGM held on June 17, 2024?

All resolutions presented at Poolbeg Pharma's AGM on June 17, 2024, were approved by shareholders.

What is Poolbeg Pharma's stock symbol?

Poolbeg Pharma is traded under AIM:POLB and OTCQB:POLBF.

What is the focus of Poolbeg Pharma?

Poolbeg Pharma focuses on developing and commercializing innovative medicines for diseases with high unmet medical needs.

Did Poolbeg Pharma provide any specific financial data in their AGM announcement?

No, the announcement did not include specific financial data.

POOLBEG PHARMA PLC

OTC:POLBF

POLBF Rankings

POLBF Latest News

POLBF Stock Data

75.50M
426.83M
24.71%
1.23%
Biotechnology
Healthcare
Link
United States of America
London